The EFS Knockout HAP1 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population targeting the EFS gene in the human HAP1 near-haploid cell line. This product provides a genetically disrupted EFS locus, generating a loss-of-function model for studying EFS-dependent processes in integrin signaling, focal adhesion dynamics, and cell migration. The polyclonal nature of the population offers a heterogeneous pool of EFS-disrupted alleles, circumventing clonal selection biases while maintaining the near-haploid genetic background for robust functional analyses.
HAP1 cells are derived from the KBM-7 chronic myeloid leukemia line and are characterized by a near-haploid karyotype, which simplifies genetic manipulation and interpretation of knockout phenotypes. The haploid state ensures that targeted disruption of a single allele effectively eliminates EFS protein expression, reducing genetic redundancy and enabling clear dissection of signaling pathways. This host cell background is widely adopted for studying cancer-relevant processes, including adhesion, motility, and survival, and provides a consistent platform for high-throughput or comparative studies.
EFS encodes a scaffolding protein that couples integrin engagement to downstream signaling cascades. It is activated by integrin receptors and functions downstream of focal adhesion kinase (FAK) and Src kinase. EFS directly interacts with CRK, DOCK180, C3G, FAK, and Src, forming complexes that drive focal adhesion turnover and cytoskeletal remodeling. These interactions promote activation of Rho GTPases, actin reorganization, and MAPK pathway stimulation, thereby regulating cell migration and adhesion. Disruption of EFS abrogates these molecular linkages, impairing the coordination between extracellular matrix sensing and intracellular motility machinery.
In the HAP1 chronic myeloid leukemia context, EFS knockout provides a valuable model to investigate integrin-mediated signaling in a cancer cell lineage. Loss of EFS disrupts focal adhesion dynamics and migratory capacity, mimicking deficits observed in adhesion-related pathologies. The near-haploid background minimizes genetic compensation, allowing researchers to attribute phenotypic changes directly to EFS disruption. This model is particularly relevant for understanding how cancer cells modulate adhesion to invade tissues and metastasize, as EFS is implicated in pathways that regulate cell-substratum interactions.
This knockout product is suitable for a range of advanced research applications, including wound healing assays to assess collective migration, transwell migration and invasion assays to quantify motility, and immunofluorescence staining of focal adhesion markers such as vinculin or paxillin. Western blotting for phospho-FAK (Tyr397) and phospho-Src (Tyr416) can be used to monitor integrin signaling status, while co-immunoprecipitation enables study of EFS-containing protein complexes. Cell adhesion assays on defined matrices further dissect attachment strength. For additional details and technical inquiries, please contact Ascent Research.
